How Can Emerging Biotechs Ensure Their Collaboration with CROs is Successful?

As the complexity of drug discovery and development steadily increases, so do the costs. With average expenditures for prescription drug R&D ranging between $2.5 and $3 billion, small and medium-sized biotech companies are facing a number of challenges. In 2018, more than two-thirds of late-stage pipelines were owned by emerging biotechs, reflecting a shift within the industry from large biopharma companies to small and medium-sized enterprises (SMEs). Often limited by a lack of liquidity, in-house resources, infrastructure, or expertise, emerging biotechs are continuously looking for more cost-effective ways to develop medicines.

Spotlight

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders.

OTHER ARTICLES
MedTech

Better Purification and Recovery in Bioprocessing

Article | October 7, 2022

In the downstream portion of any bioprocess, one must pick through the dross before one can seize the gold the biotherapeutic that the bioprocess was always meant to generate. Unfortunately, the dross is both voluminous and various. And the biotherapeutic gold, unlike real gold, is corruptible. That is, it can suffer structural damage and activity loss. When discarding the dross and collecting the gold, bioprocessors must be efficient and gentle. They must, to the extent possible, eliminate contaminants and organic debris while ensuring that biotherapeutics avoid aggregation-inducing stresses and retain their integrity during purification and recovery. Anything less compromises purity and reduces yield. To purify and recover biotherapeutics efficiently and gently, bioprocessors must avail themselves of the most appropriate tools and techniques. Here, we talk with several experts about which tools and techniques can help bioprocessors overcome persistent challenges. Some of these experts also touch on new approaches that can help bioprocessors address emerging challenges.

Read More
MedTech

Next-Gen Genetics Cancer Therapies Creating Investment Prospects

Article | September 22, 2022

Genetic therapeutics such as genetic engineering and gene therapy are increasingly emerging as one of the most influential and transformed biotechnological solutions around the globe in recent times. These genetic solutions are being assessed across various medical domains, including cancer treatment, neurology, oncology, and ophthalmology. Citing the trend, the genetics industry is estimated to experience a tsunami of approvals, with over 1,000 cell and gene therapy clinical trials currently underway and over 900 companies worldwide focusing on these cutting-edge therapies. Growing Cancer Encourages Advancements in Genetic Technologies With the surging cases of cancers such as leukemias, carcinomas, lymphomas, and others, patients worldwide are increasing their spending on adopting novel therapeutic solutions for non-recurring treatment of the disease, such as gene therapy, genetic engineering, T-cell therapy, and gene editing. As per a study by the Fight Cancer Organization, spending on the treatment of cancer increased to $200.7 billion, and the amount is anticipated to exceed $245 billion by the end of 2030. Growing revenue prospects are encouraging biotechnology and biopharmaceutical companies to develop novel genetic solutions for cancer treatment. For instance, Bristol-Myers Squibb K.K., a Japanese pharmaceutical company, introduced a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, Abecma, for the treatment of relapsed or refractory (R/R) multiple myeloma in 2022. Amid a New Market: Genetics Will Attract Massive Investments Despite several developments and technological advancements, genetics is still considered to be in a nascent stage, providing significant prospects for growth to the companies that are already operating in the domain. Genetics solutions such as gene therapies, gene editing, and T-cell immunotherapy are emerging as highly active treatments across various medical fields, resulting in increasing research and development activities across the domain, drawing significant attention from investors. Given the potential of genetic treatments and the focus on finding new ways to treat cancer and other related diseases, it's easy to understand why companies are investing in the domain. For instance, Pfizer has recently announced an investment of around $800 million to construct development facilities supporting gene therapy manufacturing from initial preclinical research through final commercial-scale production. Due to these advancements, cell and gene therapies are forecast to grow from $4 billion annually to more than $45 billion, exhibiting growth at a 63% CAGR. The Future of Genetics Though there is a significant rise in advancement in genetic technologies and developments, the number of approved genetic treatments remains extremely small. However, with gene transfer and CRISPR solutions emerging as new modalities for cancer treatment, the start-up companies will attract a growing amount and proportion of private and public investments. This is expected present a tremendous opportunity for biopharma and biotechnology investors to help fund and benefit from the medical industry's shift from traditional treatments to cutting-edge genetic therapeutics in the coming years.

Read More
Medical

2 Small-Cap Biotech Stocks You Haven't Heard of, But Should Know About

Article | August 16, 2022

With everything that's going on with the COVID-19 pandemic, many healthcare companies have grabbed plenty of spotlight during these challenging times. At the same time, a number of otherwise promising businesses have slipped under the radar. That's especially true for small-cap biotech stocks that aren't actively involved in developing tests, vaccines or treatments for COVID-19. Vaccine developers, protective equipment producers, and healthcare service providers are all attracting plenty of attention during this pandemic, but there are just as many promising biotech stocks that aren't involved in these areas. Here are two such companies that you might have missed, but they deserve a spot on your watch list.

Read More

5 Biotech Stocks Winning the Coronavirus Race

Article | April 13, 2020

There are quite a few companies that have found ways to grow their business during the ongoing COVID-19 pandemic. This is especially true for a number of biotechs now working on developing a potential treatment for, or vaccine against, the virus; shares of such companies have largely surged over the past couple of months. Although many of these treatments and vaccines are still have quite a way to go before they're widely available, it's still worth taking some time to look through what's going on in the COVID-19 space right now. Here are five biotech stocks that are leading the way when it comes to addressing COVID-19. Regeneron Pharmaceuticals (NASDAQ:REGN) wasn't among the initial wave of companies to announce a potential COVID-19 drug. However, investor excitement quickly sent shares surging when the company announced that its rheumatoid arthritis drug, Kevzara, could help treat COVID-19 patients.

Read More

Spotlight

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders.

Related News

European Biotechs Showcase Multiple Sclerosis Treatments in Stockholm

Labiotech.eu | September 17, 2019

Genmab, GeNeuro and other companies presented their latest data on next-generation treatments for multiple sclerosis at a conference in Stockholm. The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) gathered experts and companies working on multiple sclerosis in Sweden this year. Companies such as Genmab and GeNeuro revealed the progress of their treatments, with Genmab’s drug at the verge of reaching the market. Multiple sclerosis is a neurological autoimmune condition where the immune system attacks the cells that keep nerve cells healthy, causing neurodegeneration and eventual disability. Its has received attention from the biotech industry because the condition has no cure, and there are limited drugs approved to slow the progression of the disease. In particular, many companies aim to stop relapses in the most common form of the condition, known as relapsing-remitting multiple sclerosis. The Danish antibody developer Genmab presented results from its drug ofatumumab, which is licensed to Novartis. In two phase III trials, the ability of the antibody drug to prevent relapse was compared to that of teriflunomide, an oral drug routinely used to treat relapsing forms of multiple sclerosis. Patients given Genmab and Novartis’ antibody had an annualized relapse rate of around 0.1 in the two trials, which is less than half of those given teriflunomide in both trials, with an annualized relapse rate of around 0.22.

Read More

Fund for Late-Stage European Biotechs Closes Final Round With 120M Euors

labiotech.eu | June 25, 2019

The Luxembourg-based investor Vesalius Biocapital III has completed the final closing of a €120M fund to boost late-stage life science companies. Around 10-15 companies will receive investments from the fund, including specialists in drug development, med-tech, and diagnostics. Three companies have become beneficiaries so far, including the Finnish women’s health drug company Forendo Pharma, German prosthetics company Mecuris, and US digital therapy company SWORD Health. Vesalius Biocapital has secured more than €65M for the first closing of a new fund targeting European biotechs in late stages of development. Vesalius Biocapital has announced today the first closing of its third fund, VBC III, which will be aimed at biotech companies developing not only drugs and diagnostics, but also medtech and digital health products. Unlike the first two funds, VBC III will focus the investments on companies at late stages of development and closer to the market. The first closing has secured Vesalius over €65M. Over the following 18 months, the investment firm is aiming to reach €150M for the final closing. This objective is way higher than for previous funds, but the number of companies invested in, 10 to 15, will not increase; late development stages require bigger injections.

Read More

Ocular Biotechs Histogenics, Ocugen Announce Stock-For-Stock Merger

Histogenics Corporation | April 08, 2019

Histogenics Corporation and privately held Ocugen announced a merger Monday that will create a new, Nasdaq-listed company aiming to develop novel ocular gene therapies and biotherapeutics under the Ocugen name. The agreement calls for Ocugen stockholders to become the majority owners of outstanding Histogenics common stock upon closing. The deal is a stock-for-stock transaction. Upon closing, the combined company will be headquartered in Malvern, Pennsylvania and will operate under Ocugen's present leadership, the companies said. No Histogenics employees will remain employed by the combined company, according to Monday's announcement.

Read More

European Biotechs Showcase Multiple Sclerosis Treatments in Stockholm

Labiotech.eu | September 17, 2019

Genmab, GeNeuro and other companies presented their latest data on next-generation treatments for multiple sclerosis at a conference in Stockholm. The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) gathered experts and companies working on multiple sclerosis in Sweden this year. Companies such as Genmab and GeNeuro revealed the progress of their treatments, with Genmab’s drug at the verge of reaching the market. Multiple sclerosis is a neurological autoimmune condition where the immune system attacks the cells that keep nerve cells healthy, causing neurodegeneration and eventual disability. Its has received attention from the biotech industry because the condition has no cure, and there are limited drugs approved to slow the progression of the disease. In particular, many companies aim to stop relapses in the most common form of the condition, known as relapsing-remitting multiple sclerosis. The Danish antibody developer Genmab presented results from its drug ofatumumab, which is licensed to Novartis. In two phase III trials, the ability of the antibody drug to prevent relapse was compared to that of teriflunomide, an oral drug routinely used to treat relapsing forms of multiple sclerosis. Patients given Genmab and Novartis’ antibody had an annualized relapse rate of around 0.1 in the two trials, which is less than half of those given teriflunomide in both trials, with an annualized relapse rate of around 0.22.

Read More

Fund for Late-Stage European Biotechs Closes Final Round With 120M Euors

labiotech.eu | June 25, 2019

The Luxembourg-based investor Vesalius Biocapital III has completed the final closing of a €120M fund to boost late-stage life science companies. Around 10-15 companies will receive investments from the fund, including specialists in drug development, med-tech, and diagnostics. Three companies have become beneficiaries so far, including the Finnish women’s health drug company Forendo Pharma, German prosthetics company Mecuris, and US digital therapy company SWORD Health. Vesalius Biocapital has secured more than €65M for the first closing of a new fund targeting European biotechs in late stages of development. Vesalius Biocapital has announced today the first closing of its third fund, VBC III, which will be aimed at biotech companies developing not only drugs and diagnostics, but also medtech and digital health products. Unlike the first two funds, VBC III will focus the investments on companies at late stages of development and closer to the market. The first closing has secured Vesalius over €65M. Over the following 18 months, the investment firm is aiming to reach €150M for the final closing. This objective is way higher than for previous funds, but the number of companies invested in, 10 to 15, will not increase; late development stages require bigger injections.

Read More

Ocular Biotechs Histogenics, Ocugen Announce Stock-For-Stock Merger

Histogenics Corporation | April 08, 2019

Histogenics Corporation and privately held Ocugen announced a merger Monday that will create a new, Nasdaq-listed company aiming to develop novel ocular gene therapies and biotherapeutics under the Ocugen name. The agreement calls for Ocugen stockholders to become the majority owners of outstanding Histogenics common stock upon closing. The deal is a stock-for-stock transaction. Upon closing, the combined company will be headquartered in Malvern, Pennsylvania and will operate under Ocugen's present leadership, the companies said. No Histogenics employees will remain employed by the combined company, according to Monday's announcement.

Read More

Events